))
ADALTA LIMITED (1AD) - Revolutionizing Biotechnology: CEO Tim Oldham on i-body Platform and Breakthroughs in Fibrotic Disease Therapeutics
Manage episode 432531957 series 3570035
Content provided by Andrew Musgrave. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Andrew Musgrave or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://player.fm/legal.
What if you could harness the secrets of the shark immune system to combat diseases that have stumped traditional medicine? On this episode of ASX Briefs, we sit down with Tim Oldham, CEO of AdAlta Limited, to uncover how his team is revolutionizing biotechnology with their pioneering i-Body platform. From the depths of shark biology to cutting-edge drug discovery, Tim unfolds the extraordinary journey of creating ultra-small, highly specific protein therapeutics aimed at tackling fibrotic diseases.
Join us as Tim dives into the progress of AD-214, AdAlta’s promising candidate currently in clinical trials for idiopathic pulmonary fibrosis (IPF). With half a million people affected worldwide and no therapies to halt fibrosis progression, AD-214 offers genuine hope. We also explore the strategic directions of AdAlta's subsidiaries, AdSolis and Adcella, and how they’re pushing the boundaries of therapeutic development. Whether you’re a biotech enthusiast or just curious about ground-breaking medical innovations, this conversation is packed with insights you won’t want to miss.
44 episodes
Share
